Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07445295) titled 'Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma' on Feb. 25.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Chipscreen Biosciences, Ltd.
Condition:
Metastatic Pancreatic Ductal Adenocarcinoma
Intervention:
Drug: Chiauranib
Drug: Toripalimab Injection
Drug: Albumin-paclitaxel Injection
Drug: Gemcitabine Injection
Drug: Chiauranib placebo
Recruitment...